Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

Core Viewpoint - The Swiss pharmaceutical company is acquiring a new asset to enhance its existing pipeline of treatments for neuromuscle disorders [1] Company Summary - The acquisition is aimed at complementing the company's current offerings in the neuromuscle disorder treatment space [1]